EYE

NOVA EYE FPO [EYE]

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Healthcare · ASX Small Cap

$0.1350 +3.8%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 4 consecutive scansFirst seen: 2026-03-23

Get alerts when EYE triggers a new signal

Free watchlist with daily scans for 2,200+ ASX stocks

Track EYE — Free

Active Signals

Bullish Signals

Stochastic just turned bullish from a low level — early reversal sign
Lagging the Small Ords index — relative strength of 0.89, underperforming its peers
Critical cash runway (1.2 quarters)
Low P/S ratio (1.1x)
Moderate revenue growth (+11%)
EPS estimates revised upward (+10pts)
Small-cap ($20-100M)
CANSLIM I: Institutional ownership (18%)
Sentiment is mixed — no strong consensus either way
The bigger volume days are the up days — volume-weighted momentum is positive (1.62%/day)
RBA hiking (-3pts)

Risk Signals

Below the 200-day average — the long-term trend is still working against it
Negative profit margins (-12%)
Not enough chatter to gauge sentiment — defaulting to neutral

Ask Scout AI about EYE

"What's driving EYE today?" "How does EYE compare to peers?" "Key risks for EYE?"

3 free messages/day · Unlimited with Pro

Recent Catalysts

LOW AGM date and closing date for Director Nominations

LOW Appendix 4E and Annual Report

NONE Appendix 3 Y T A Spurling

NONE Appendix 4G and Corporate Governance Statement

NONE Full Year Financial Results

Recent ASX Announcements

2026-09-03	AGM date and closing date for Director Nominations
2026-08-28	Appendix 3 Y T A Spurling
2026-08-26	Appendix 4G and Corporate Governance Statement
2026-08-26	Full Year Financial Results PRICE SENSITIVE
2026-08-26	Appendix 4E and Annual Report PRICE SENSITIVE

Key Metrics

$38.5M

Market Cap

199K

Avg Volume

1.4x

Vol Ratio

$0.10 — $0.20

52-Week Range

N/A

Short Interest

N/A

Cash Runway

-26.1%

ROE

-12.4%

Profit Margin

CANSLIM Analysis

	Factor	Rating	Detail
C	Current EPS	fail	EPS Growth: 0%
A	Annual Earnings	fail	CAGR: 0%
N	New Highs / Catalysts	neutral
S	Supply & Demand	neutral	Float: 82%
L	Leader vs Laggard	pass	RS: 6
I	Institutional Sponsorship	pass	Inst: 18%
M	Market Direction	neutral	Neutral